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hronic obstructive pulmonary disease (COPD) and lung cancer are both life-limiting 
diseases that confer burden in the form of symptoms and impacts on functioning and 
quality of life. Comparing burden between these diseases is of interest to determine 
whether people with COPD require improved access to Specialist Palliative Care. 
Access should be based on needs rather than diagnosis or prognosis but is limited 
for people with COPD compared to lung cancer. 
 
Aim 
To synthesise research comparing burden from COPD and lung cancer to estimate 
relative need for Specialist Palliative Care. 
 
Design 
A systematic review was conducted of observational quantitative studies published in 
English peer-reviewed journals comparing burden from COPD and lung cancer 
(PROSPERO CRD42018108819). No limits were placed on disease stage. Meta-
analyses were performed where studies used the same measure; otherwise, 
synthesis used a narrative approach. Risk of bias was assessed using the Agency 
for Healthcare Research and Quality tool. 
 
Data sources 






Of 790 articles returned, 13 were included, reporting 11 studies. Risk of bias was 
generally moderate. Except for pain, burden tended to be at least as substantial from 
COPD as lung cancer, with breathlessness and impacts on functioning being even 




Efforts should be made to ensure that access to Specialist Palliative Care is 
commensurate with COPD’s substantial and long-lasting burden. Future research 
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Key statements 
What is already known about the topic 
 Chronic obstructive pulmonary disease (COPD) and lung cancer are both life-
limiting diseases that confer burden in the form of symptoms and impacts on 




 People with COPD are less likely to access Specialist Palliative Care than 
those with lung cancer, despite consensus that this should be based on needs 
rather than diagnosis or prognosis. 
What this paper adds 
 This systematic review shows that – with the exception of pain - most aspects 
of burden tend to be at least as substantial from COPD as from lung cancer, 
and breathlessness and impairments in functioning may be significantly 
worse. 
 Longitudinal studies suggest that people with COPD often live with burden for 
longer.  
Implications for practice, theory, or policy. 
 Increased efforts should be made to ensure that people with COPD access 
Specialist Palliative Care to assist with managing their disease burden.  
 Future research is needed to understand interactions between different levels 
of burden and other factors in each diagnostic group to inform disease-







Lung cancer and chronic obstructive pulmonary disease (COPD) have much in 
common. Both are lung diseases that affect adults mostly in mid to later life and are 
among the most common smoking-related causes of death globally (1). Both 
diseases cause significant burden in the form of symptoms and adverse impacts on 
functioning and quality of life (2, 3).  
 
Disease burden and its measurement by means of patient-reported outcomes has 
been taxonomised within an influential model by Wilson and Cleary (1995) (4). This 
model delineates four ‘levels’ of outcome based on their more ‘proximal’ or ‘distal’ 
relationship to biological/physiological variables associated with disease and 
treatment, namely: symptoms, functioning, general health perceptions, and overall 
quality of life. More distal outcomes are assumed to be determined by flow-on effects 
from proximal problems, with mediation by personality and environmental factors 
such as social support.  
 
The pathophysiologies of lung cancer and COPD both centre on the lungs but differ 
with regard to trajectory, treatment and prognosis. In their advanced stages, both 
diseases share respiratory symptoms of breathlessness and cough, with 
breathlessness being the most common and burdensome, especially in COPD (5, 6). 
Studies have demonstrated associations between symptoms, functioning and quality 
of life that are consistent with symptoms having flow-on impacts to other aspects of 





People with lung cancer and COPD differ substantially in terms of access to 
Specialist Palliative Care. Specialist Palliative Care is a relatively recent sub-
specialty of medicine that provides interdisciplinary care across settings to optimise 
quality of life and mitigate suffering among people with life-limiting illness (9). 
Available data suggest that people with COPD may be at least four times less likely 
to be referred to Specialist Palliative Care compared to people with lung cancer (10, 
11). A large scale study across 14 countries (N=5,568,827) found that people with 
COPD were also less likely than those with lung cancer to die at home or in a 
palliative care institution, and more likely to die in a hospital or a nursing home (12). 
Smaller studies from the United States and Taiwan have found that people with 
COPD are also more likely to access aggressive but clinically futile care at the end of 
life, including admission to intensive care, ventilation, tube feeding and attempted 
cardiopulmonary resuscitation (13, 14).   
 
While, historically, Specialist Palliative Care has focused largely on people with 
cancer in the last weeks or even days before death, contemporary referral criteria 
are based on need for “early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychosocial and spiritual” (15) at 
any stage after it is recognised that the person has a life-limiting illness, and 
regardless of diagnosis. There is a concern that people with COPD may be less 
likely than people with lung cancer to be referred to Specialist Palliative Care, not 
because they have lesser need, but because clinicians have been slow to move to a 
needs- rather than diagnosis-/prognosis-based model for referral (12, 16-18), driving 
inequality in Specialist Palliative Care access (19). These concerns are consistent 




if not greater, burden than lung cancer, and over a longer period (20). However, this 
review was not systematic and may, therefore, have been subject to bias in terms of 
study selection and synthesis. 
 
The current authors set out to systematically review the evidence comparing burden 
from lung cancer and COPD to provide a more definitive answer to the research 
question, ‘is burden from COPD in terms of symptoms and adverse impacts on 
functioning and quality of life as substantial as from lung cancer’? 
 
Methods 
A systematic review protocol was registered in the PROSPERO prospective 
international register of systematic reviews (CRD42018108819) and is reported in 
accordance with the Preferred Reporting Items for Systematic Review and Meta-
analysis (PRISMA) statement (21). 
 
Eligibility criteria 
To be eligible, articles needed to report studies comparing burden from COPD and 
lung cancer in the context of usual care and published in an English-language, peer-
reviewed journal. We excluded studies describing burden in one patient group only 
because of reduced validity in comparing samples not drawn from the same 
population or using data for secondary analysis. No limits were set for stage of 
disease. Studies needed to be quantitative and observational but could be cross-
sectional or longitudinal. While qualitative studies provide in-depth insights into lived 
experience of disease, the current review focused on estimates derived from 




groups. No restrictions were set for date of publication. Measures of burden were 
defined and classified according to Wilson and Cleary’s (1995) model of patient 
reported outcomes (4). Functioning measures were considered to include those of 
performance status or activities of daily living.  
 
Information sources 
The electronic databases Medline, Cumulative Index to Nursing and Allied Health 
(CINAHL) and PsycINFO were searched in September 2018 and updated in 
September 2019. These databases were chosen as the most extensive repositories 
of published research in the disciplines of medicine, nursing/allied health and 
psychology respectively. The reference lists of the previous non-systematic review 
(20) and included articles were hand searched for further relevant articles. Where 
necessary, article authors were contacted by email to request additional summary 
data to enable meta-analysis. 
 
Search 
Search terms were developed through a preliminary search of Medline in 
consultation with a university librarian. Subject headings and keywords related to 
lung cancer or COPD combined with breathlessness, performance status and 
functioning, and quality of life (see Supplementary Table 1). Symptom-related search 
terms were limited to breathlessness because this is the symptom most often 
referred to as common between lung cancer and COPD. Databases were searched 






Articles returned from database searches were imported into EndNote (version X8). 
Initially, two researchers (TL and ASM) independently screened the titles/abstracts of 
10% of articles against eligibility criteria, each obtaining full-texts as required to 
decide inclusion/exclusion. After finding >95% agreement, screening for the 
remaining articles was continued by one reviewer alone (ASM).  
 
Data collection and items 
A single reviewer (ASM) extracted data using an MS Excel proforma, with random 
checks conducted by a second reviewer (TL). Data items included author, year of 
publication, country, setting, study design, aims, sample characteristics (size, 
diagnoses, stage of disease, age and gender), outcome measures, results and 
author conclusions.  
 
Risk of bias in individual studies 
To assess risk of bias, we used a version of the Agency for Healthcare Research 
and Quality (AHRQ) tool (22) that was adapted for observational studies comparing 
two groups (23). This tool assessed: selection bias (uniformity of inclusion/exclusion 
criteria and comparability of groups on confounding variables); performance bias 
(definition of disease groups using standardised systems); detection bias (validity of 
outcome assessment, and control of confounding variables); and attrition bias 
(handling of missing data). Each study was appraised for bias by two researchers 
working independently (TL and ASM), who then discussed to reach consensus on 





Synthesis of results 
A meta-analysis was conducted where data were available on the same outcome 
measure from two or more studies. Where studies were prospective, baseline data 
were selected for inclusion in meta-analyses. Random effects models were used to 
allow for the possibility that between-study differences varied according to 
differences in sample characteristics (24). Summary measures were mean 
differences between disease groups with 95% confidence intervals (CIs). 
Heterogeneity was estimated using the Cochrane I2 statistic, and interpreted 
according to the Cochrane Handbook of Systematic Reviews as follows: 0% to 40% 
unimportant, 30% to 60% moderate, 50% to 90%: substantial, and 75% to 100% 
considerable heterogeneity (25).  
 
Where data were unavailable to conduct a meta-analysis, synthesis used a narrative 
approach based on methods described by Popay et al. (2006) (26). We followed 
these authors in recognising that ‘vote counting’ the number of studies favouring 
each group can be a useful first step in synthesis provided that results are 
interpreted with acknowledgement that studies are unlikely to deserve equal ‘weight’ 
due to differences in reliability of estimates and risk of bias. Results for symptoms, 
functioning, health perceptions and quality of life were grouped according to whether: 
1) all available studies exclusively found them to be worse in one disease group than 
the other; 2) all available studies either found them to be worse in one disease or 
found no difference; 3) studies sometimes found them to be worse in one disease 
group but in other studies vice-versa, or 4) no available study found a significant 




conducted of differences in study characteristics and risk of bias that might explain 
why studies differed in their results. As well as statistical differences, narrative 
synthesis was concerned with whether between-group differences were clinically 
important. To standardise measurement across measures, a rule of thumb was 
adopted of 0.5 standard deviation (SD) for comparisons of mean scores (27). An 
exception was made for the Karnofsky Performance Scale (KPS) (28) measure of 
functioning, which is scored in increments of 10 (e.g. 20, 30) rather than single units. 
To be regarded as a clinically important difference on the KPS, a between-group 
mean difference of at least 10 points was required to suggest an average disparity of 
one or more category. 
 
Results 
Six hundred and seventy-one articles were returned by searches, of which 270 
required full-text retrieval and 13 met inclusion criteria, reporting 11 studies (see 
Figure 1) (13, 14, 29-39). Articles were excluded based on title/abstract alone 
because they were not research, did not focus on disease burden, or did not 
compare lung cancer with COPD. Bausewein et al. (2010a, 2010b) (29, 30) and 
Weingaertner et al. (2014, 2015) (31, 32) each reported a single German study in 
two articles. An article by Habraken et al. (2009) (34) reported new data both 
separately and in combination with data from a previous study that shared some of 
the same team members by Gore et al. (2000) (33). The current review considered 
original data from each of these studies separately. 
  






Included articles were published between 2000 and 2017. Five of the studies were 
conducted in Europe (29-35), two in the USA (13, 36), and one in each of Australia 
(39), China (38), Taiwan (14) and Japan (37). Collectively, the samples included a 
greater number of people with lung cancer (n=2,694) than COPD (n=1,899), due in 
large part to the Australian study, which included 1,081 people with lung cancer but 
only 199 with COPD (39). The COPD group in the Australian study also included 
people with other respiratory diseases, and the numbers with each type of disease 
were not reported. While data were reported from this study for samples with 
secondary as well as primary lung cancer, we focused on the group with primary lung 
cancer in our synthesis. In the other 10 studies, lung cancer samples were smaller 
than or equal to COPD in all studies apart from two (36, 38).  
 
Age and gender characteristics were similar between groups in all studies that 
reported these except three (14, 36, 37), one of which had significantly more men with 
COPD (37) and two of which had significantly older COPD samples (14, 36). Only the 
two US studies reported data on ethnicity, both of which included >80% Caucasian 
participants (13, 36). Disease groups were most commonly staged using the tumour, 
node and metastasis (TNM) staging for lung cancer (40) and Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) criteria for COPD (41). Table 1 
summarises the characteristics of each included study. 
 





Results of individual studies 
The measures used by each of the 11 studies to compare lung cancer with COPD 
and related results are detailed in Supplementary Table 2. Collectively, studies 
measured a wide range of domains of burden, assessing all levels of Wilson and 
Cleary’s (1995) model (4). 
 
Risk of bias within studies  
The main sources of bias arose from inconsistency in eligibility criteria across 
disease groups and less than optimal control for confounding variables. Studies by 
Bausewein et al. (2010a, 2010b) (29, 30) and Weingaertner et al. (2014, 2015) (31, 
32) were rated as lowest risk of bias overall, although were also two of the smaller 
studies in terms of sample size (N=109 and N=82 respectively). Results from risk of 
bias assessment are summarised in Table 2. 
 
Table 2 about here 
 
Synthesis of results 
Table 3 summarises results from vote counting for each domain of burden (i.e. the 
numbers of studies finding COPD or lung cancer to be worse, or no significant 
difference). The numbers of studies finding burden to be worse in COPD than lung 
cancer were generally higher than vice-versa, with the notable exception of pain, 
which was found to be worse in lung cancer in 5/8 studies. 
 





An exploration of equivocal results is presented for each level of burden as follows. 
Across measures, there were no discernible patterns in results according to sample 
size or risk of bias. The studies that most consistently found significant differences 
were mid-ranking in risk of bias and small to moderately sized (33, 35, 38). 
 
Symptoms 
Breathlessness (or dyspnoea/shortness of breath/chest tightness) was among the 
most commonly measured symptom, and was found either to be worse in COPD or 
not significantly different. A German study by Bausewein et al. (2010a, 2010b) (29, 
30) found results to be mixed on the Memorial Symptom Assessment Scale Short 
Form (MSAS-SF) (42) versus Modified Borg Dyspnea Scale (MBS) (43). Bausewein 
et al. found the proportion with shortness of breath and severity of distress due to 
breathlessness to be higher in COPD than lung cancer on the MSAS-SF, but found 
no significant difference on the MBS. A meta-analysis of the MBS that included 
Bausewein et al.’s study and another German study by Weingaertner et al. (2014, 
2015) (31, 32) found the overall difference between people with lung cancer 
compared with COPD also to be non-significant, but with substantial heterogeneity (-
0.71, 95% CIs -1.98 to 0.56, I2 79%) (Figure 2). Compared to Weingaertner et al.’s 
study and some others that found breathlessness to be worse in COPD, Bausewein 
et al.’s sample included a lower proportion of COPD patients with GOLD stage IV 
versus III disease as well as a higher proportion of lung cancer patients with 
metastatic disease, and a lower proportion of male patients. However, these 
differences were not always consistent, and reporting of disease stage varied.  
 





The study by Bausewein et al. (2010a) was one of three longitudinal studies that 
tracked breathlessness and/or distress up until death and identified these symptoms 
to worsen later in the lung cancer than COPD trajectories (29, 31, 39). One of these 
longitudinal studies was the only one that enabled assessment of between-group 
differences in breathlessness in terms of clinical importance; breathlessness was 
worse in COPD to a clinically important extent (≥ 0.5 SD) at all three timepoints (39). 
The study by Bausewein et al. (2010a) identified individual variations in 
breathlessness corresponding to four different patterns: fluctuation, increasing, 
stable and decreasing breathlessness (29). While people with lung cancer differed 
from people with COPD regarding the relative frequency of these patterns, all four 
patterns were observed in both groups.  
 
Bausewein et al.’s (2010a, 2010b) (29, 30) results on the Hospital Anxiety and 
Depression Scale (HADS) (44) were typical of studies measuring anxiety and 
depression in finding there to be no significant between-group differences. This 
finding was upheld even when combined in meta-analyses with a UK study by Gore 
et al. (2000) (33) that found both anxiety and depression to be significantly worse in 
COPD (anxiety -1.80, 95% CIs -6.41 to 2.80; depression -1.03, 95% CIs -4.86 to 
2.70) (Figure 2). Gore et al.’s lung cancer sample differed from Bausewein et al.’s in 
terms of being mostly (72%) men and having received palliative care radiotherapy 
over the last 12 months in 80% of cases. It was less clear what might have led other 
studies to differ from the majority by finding depression to be worse in COPD (34, 




these studies were either mixed (13, 34) or less than the 0.5 SD taken to suggest a 
clinically important difference (35). 
 
Figure 3 about here 
 
As noted above, most studies measuring pain found this to be worse in lung cancer 
than COPD. The only study that found pain to be worse in COPD was the study by 
Gore et al. (2000) (33), in which pain in the lung cancer sample may have been 
substantially managed by palliative radiotherapy. 
 
Sample characteristics may have also been a factor to findings on vitality. The study 
by Gore et al. (2000) found vitality to be worse in COPD (33), whereas a Dutch study 
by Habraken et al. (2009) found no between-group differences for this symptom (34). 
Habraken et al. enrolled disproportionately more people with COPD than with lung 
cancer (n=82 vs. n=19) and focused on outpatients only, whereas Gore et al. 
included inpatients as well. 
 
Functioning 
Seven studies measured functioning, all of which identified impairments to be worse 
in COPD, except for the study by Bausewein et al. (2010a/2010b) (29, 30), which 
again found no difference. A meta-analysis that included this study alongside four 
others that used the Karnofsky Performance Scale (KPS) (28) found functioning to 
be significantly better for people with lung cancer than COPD overall (7.64, 95% CIs 




analysis included a (10 point) categorical difference only at the upper end, 
questioning the clinical importance of the overall estimate.  
 
Figure 4 about here 
 
Differences between the samples of Bausewein et al. (2010a/2010b) and those of 
Gore et al. (2000) and Weingaertner et al. (2014, 2015) are noted above. Compared 
with Bausewein et al.’s (2010a/2010b) sample, the Serbian sample of Maric et al. 
(2016) had more men and a higher proportion of patients with metastatic disease in 
the lung cancer group. No important differences were observed between Habraken 
et al.’s (2000) Dutch sample and Bausewein et al.’s (2010a/2010b), but comparisons 
were hampered by limited and inconsistent reporting. Habraken et al (2000) reported 
that 23% and 73% of their COPD and lung cancer samples respectively died within a 
year of data collection, compared to 10% and 62% within 6 months for Bausewein et 
al. (2010a/2010b). 
 
Studies that used measures of functioning other than the KPS found that patients 
with COPD compared to lung cancer had greater dependencies on activities of daily 
living in COPD versus lung cancer on the Katz Activities of Daily Living (13) and 
were less likely to have high functioning denoted by the Palliative Performance Scale 
(36). Neither study enabled assessment of clinical importance against the threshold 





General health perceptions 
Three studies used the Medical Outcomes Study Short Form 36 (SF-36) (45) to 
measure health perceptions, all of which found these to be less positive in people 
with COPD than lung cancer (33-35).This scale is based on a single question, 
namely: “In general, would you say your health is: excellent/very 
good/good/fair/poor?”. Between-group differences in the two studies that reported 
scores rather than just p-values (34, 35) were in excess of the (46)0.5 SD assumed 
to indicate a clinically important difference. 
 
Quality of life 
The same three studies reported results on other scales from the SF-36 (47) on 
quality of life but reported these in ways that precluded a meta-analysis. In all three 
cases, SF-36 scales either registered lower quality of life in COPD or no significant 
difference. However, only physical functioning was found to be significantly worse in 
COPD across all three studies, and differences rarely met criteria for clinical 
importance where means/SDs were reported.  
 
A Taiwanese study that used the McGill Quality of Life (MQOL) Questionnaire (37) 
found mixed results, with social support worse in COPD but psychological support 
worse in lung cancer, and no significant difference on physical symptoms/problems. 
This study was one of three to measure global or overall quality of life via a single 






The three studies that used the SF-36 also administered disease-specific quality of 
life measures, but these could not be compared between groups because measures 
necessarily differed between lung cancer and COPD (33-35).  
 
Other measures 
Measures that could not be readily classified using Wilson and Cleary’s (1995) 
model (4) included sub-scales of the Palliative Outcome Scale (POS) (48) assessing 
palliative care needs relating to information, sharing feelings, practical matters and a 
feeling of time being wasted on healthcare appointments, and the  Functional 
Assessment of Chronic Illness Therapy (FACIT) measure of spiritual wellbeing (the 
FACIT-SP-12) (49). These scales identified no significant differences between 
groups, except for the POS scale, which found people with lung cancer to fare worse 






With the notable exception of pain, the current systematic review suggests that most 
aspects of burden are at least as substantial from COPD as from lung cancer, and 
that breathlessness and impairments in functioning may be significantly worse. 
Longitudinal studies indicate that symptoms tend to present later in the lung cancer 
disease trajectory, suggesting that people with COPD are also likely to live with 
disease burden for longer (29, 31, 39). These findings confirm and extend those of a 
non-systematic review published in 2012 (20). 
 
Results from this review are consistent with concerns that people with COPD may be 
disadvantaged by limited access to Specialist Palliative Care, a specialty specifically 
aimed at easing burden from life-limiting disease. Research on health professional 
knowledge, attitudes and beliefs suggests that barriers to Specialist Palliative Care 
access for people with COPD may stem from difficulties with prognosticating and a 
commensurate reluctance to discuss end of life care for fear of undermining hope 
(50, 51). While both COPD and lung cancer are life-limiting, mean survival time from 
diagnosis is approximately five times longer for people with COPD (30). Symptoms 
may emerge, present and be interpreted differently for each disease during their 
respective trajectories. Breathlessness is more insidious in people with COPD and 
may therefore be less likely to trigger clinical attention compared to the rapid 
escalation associated with lung cancer towards the end of life (29). Also, pain tends 
to be less severe and more chronic in COPD compared to lung cancer, and is less 
well understood in terms of pathophysiology and relationship to other clinical 
features (52). Pain is assumed by many health professionals to be the main criterion 




commonly enabling access for people with lung cancer (54). A survey of Australian 
and New Zealand Respiratory specialists found that the main reasons they would 
refer someone with COPD to Specialist Palliative Care included psychosocial and 
spiritual care, carer support and end of life care (55). Educating health professional 
about disease burden from COPD and what Specialist Palliative Care can usefully 
offer to ameliorate this may be needed to support the global shift towards needs-
based referral aimed at improving access (12, 16-18).  
 
In addition to barriers to referring patients with COPD to Specialist Palliative Care, it 
is also worth noting that some services within the specialty may themselves be slow 
to move to a needs-based model. There is a paucity of research on relevant 
attitudinal barriers among Specialist Palliative Care clinicians, but a systematic 
review in 2015 of referral criteria for people with cancer found that prognosis of less 
than 1 year or even 6 months remained a requirement in some cases (56). Specialist 
Palliative Care needs to lead the way in aligning access with needs-based rhetoric, 
advocating for resources to manage the associated increase in caseloads. 
 
The differences in pathophysiology underlying COPD when compared to lung cancer 
and its influence on their respective trajectories may have implications for how 
different levels of burden interact and are affected by other factors. Comparative 
studies suggest that breathlessness is prominent within the symptom profiles for 
both diseases (29). Breathlessness also has a negative association with functioning 
of a similar magnitude for both patient groups (31). However, it cannot be assumed 
that trajectories and associations are due to the same underlying mechanisms for 




of life and socio-economic factors for people with COPD not found for the lung 
cancer sample (35), suggesting that unemployment and financial stress may have a 
greater role as mediating factors in COPD. Other research suggests that reduced 
work productivity and quality of life are associated with COPD exacerbations (57), 
perhaps through time spent in hospital and reduced activity from fear of causing a re-
occurrence (58). Potential differences of this kind are important because there has 
been an increasing trend toward delivering the same breathlessness self-
management interventions to people regardless of their diagnostic group (59). 
Further longitudinal research is needed to better understand similarities and 
differences between pathways to burden in COPD versus lung cancer to inform 
whether interventional approaches should be targeted based on disease type. 
 
Strengths and Limitations 
The systematic approach taken by this review minimised the risk of bias compared to 
those previous (20). However, a number of limitations should be noted. The most 
important of these concerns the degree to which COPD and lung cancer are 
comparable with regard to stage of disease and care received. TNM criteria 
determine the stage of lung cancer according to degree of metastases, whereas 
GOLD criteria for COPD define stage based on spirometric criteria and 
number/severity of exacerbations, as well as, more recently, breathlessness and 
COPD-specific quality of life. Samples from each group within the same studies were 
likely to have received different treatments from different services (i.e. Oncology 
versus Respiratory) even when drawn from the same hospital or community 
population. There is also likely to be variability between individual services regarding 




on whether participants had received Specialist Palliative Care which, as noted 
earlier, is more likely for patients with lung cancer than those with COPD. Service 
factors were seldom reported so could not be controlled for in analyses, and are 
likely to have contributed to differences in burden. While we sought to address 
heterogeneity by using a random effects model in our meta-analyses, the capacity of 
this approach is limited, and the small number of studies available for each 
comparison may have reduced reliability (60).  
 
A further limitation concerns the likelihood that some people in the included studies 
had both lung cancer and COPD given the relationship between tobacco smoking 
and both diseases. A systematic review of studies comparing lung cancer 
prevalence in COPD to controls estimated a summary odds ratio of 6.35 (95% CI: 
3.98–10.15) (61). Even the two studies in our pool that tried to exclude people 
presenting with both diseases (34, 35) are likely to have done so imperfectly given 
research suggesting that COPD is under-diagnosed in people with lung cancer, 
perhaps even in the majority of cases (62). Comorbidity of COPD with lung cancer 
increases burden (63, 64), as well as patients’ likelihood of receiving palliative care 
support (65).  
A final limitation concerns the ways in which included studies chose to define and 
measure burden. Burden-related constructs are often complex and multidimensional, 
and nomenclature is sometimes inconsistent and/or poorly differentiated. To 
increase the validity of comparisons, we used an established model for classifying 
different levels of burden, and confined meta-analyses to studies that used the same 
measure. This conservative approach had the disadvantage that only a small 




two studies through to five. Many authors did not report results in a way that enabled 
assessment of clinical importance as well as statistical significance. Moreover, 
qualitative research suggests that even constructs that are considered more 
proximal to the disease, such as breathlessness, may be experienced and 
interpreted differently by people with lung cancer versus COPD (66). More distal 
constructs such as quality of life are likely to be subject to a variety of complex 
factors not measured in the studies. Some, such as self-blame and stigma related to 
smoking aetiology are experienced by people in both disease groups (67, 68). 
However, there may be other constructs that are of greater salience for one group or 
the other. Symptoms experienced by people with lung cancer are likely to be more 
variable than COPD, depending on the sites of metastasis (5). Limiting our symptom-
related search terms to breathlessness may have overlooked studies measuring 
symptoms that are prevalent in only one disease, thus under-estimating symptom 
burden from one disease or other.  
 
Limiting inclusion to articles published in English has not been found to lead to 
significant publication bias in previous research (69). However, when considering the 
generalisability of results, it is worth noting that studies were conducted in a narrow 
range of countries and, with the notable exception of the US study by Claessens et 
al. (2009) (13), had sample sizes of 100 people or less in each disease group. 
 
Conclusion 
This systematic review and meta-analysis suggests that most aspects of burden are 
at least as substantial from COPD as from lung cancer, and that breathlessness and 




likely to live with burden for longer. Given that eligibility for Specialist Palliative Care 
is defined by needs rather than prognosis, efforts are needed to improve access for 
people with COPD. Further research is needed to understand the relative pathways 
underlying disease burden from COPD and lung cancer to establish whether 
disease-specific approaches are needed to alleviating burden in each case. 
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Table 1: Sample characteristics from 11 studies comparing burden from lung cancer 








Setting Sample size Stage of disease Age 























FEV1 <0.751 and 















939 1008 TNM 
Stage 
III/IV 




70/no IQR 62.2 51.3 



















Bausewein et al. 




Mixed 49  60 TNM 
Stage 
III/IV 



































129 76 Not 
indicated 




















End-stage defined by any 
of: respiratory failure 
postintubation, persistent 
hypoxia, tachycardia or 


















Setting Sample size Stage of disease Age 























hypotension, or cachexia 
with chronic malnutrition 
Weingaertner et al. 
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FEV1 - forced expiratory volume; GOLD - Global Initiative for Chronic Obstructive Lung Disease; IQR – interquartile range; SD 





Table 2: Risk of bias in 11 studies comparing burden from lung cancer with chronic 

















 Lung cancer and 










Gore et al (2000) (26) 
UK 
Y N N Y N/A N/A 
Claessens et al (2000) (8) 
USA 
N N N Y N/A N/A 
Habraken et al (2009) (27) 
Netherlands 
Y N Y Y N/A N/A 
Bausewein et al. (2010a,b) (4, 23) 
Germany 
Y N Y Y Y N 
Currow et al (2010) (32) 
Australia 
Y N N Y N Y 
Taur et al (2012) (31) 
China 
N N N Y N N/A 
Chou et al (2013) (9) 
Taiwan 
Y N N N N Y 
Weingaertner et al. (2014, 2015) 
(24, 25) 
Germany 
N Y Y Y Y N 
Wysham et al (2015) (29) 
USA 
N N N Y N/A N/A 
Maric et al (2016) (28) 
Serbia 
Y N Y Y N N/A 
Hasegawa et al (2017) (30) 
Japan 
N N Y Y N/A N/A 
 





Table 3: Number of studies finding various domains of burden to be worse in COPD 
compared to lung cancer, vice-versa, or no significant difference 
Level of burden Construct Number of studies 
Worse in 
COPD 
Worse in lung 
cancer 
No difference Total* 
Symptoms Anxiety 1 0 3 4 
 Depression 1 0 1 2 
 Mood 0 1 1 1 
 Distress 0 0 2 2 
 Suicide risk 1 0 1 1 
 Feeling sad 0 0 1 1 
 Nervousness 0 0 1 1 
 Irritability 0 0 1 1 
 Worrying 0 0 1 1 
 Feeling anxious or worried 0 1 0 1 
 Family anxious 0 1 0 1 
 Life worthwhile 0 0 1 1 
 Feeling good 1 0 0 1 
 Pain 1 6 3 9 
 Breathlessness 6 0 5 9 
 Shortness of breath 2 0 1 3 
 Chest tightness 1 0 0 1 
 Cough 0 1 2 3 
 Dysphagia 0 0 1 1 
 Dry mouth 1 0 0 1 
 Fatigue 0 2 3 4 
 Lack of energy 0 0 1 1 
 Vitality 1 0 1 2 
 Lack of strength/weakness 0 0 2 2 
 Feeling drowsy/ difficulty 
sleeping 
0 1 1 1 
 Insomnia 1 1 0 2 
 Poor appetite/anorexia 0 1 3 4 
 Weight loss 0 0 1 1 
 Nausea 0 1 1 2 
 Abdominal distention 0 1 0 1 
 Feeling bloated 1 0 0 1 
 Constipation 1 1 0 2 
 Diarrhoea 0 0 1 1 
 Urine retention 1 0 0 1 
 Sweats 0 0 1 1 
 Changes in skin 1 0 0 1 
 Pressure sores 0 1 0 1 
 Oedema 1 0 0 1 
 Delirium 0 1 0 1 
 Numbness in hands/feet 0 0 1 1 
 Thirst 1 0 0 1 




Level of burden Construct Number of studies 
Worse in 
COPD 
Worse in lung 
cancer 
No difference Total* 
 Problems with sexual activity 0 1 0 1 
 Symptoms other than pain 
and breathlessness 
0 1 0 1 
 Total number of symptoms 0 0 1 1 
 Mean severity of all 
symptoms 
1 0 0 1 
 Average frequency and 
distress caused by all MSAS 
symptoms 
0 0 1 1 
 Average frequency of four 
psychological symptoms and 
distress associated from six 
physical symptoms 
0 0 1 1 
 Average of distress 
associated with 12 physical 
symptoms 
0 0 1 1 
Functioning Performance status or 
activities of daily living 
7 0 1 8 
Health perceptions General health perceptions 3 0 0 3 
Quality of life Social support 1 0 0 1 
 Psychological support 0 1 0 1 
 Role emotional 1 0 2 3 
 Mental health 2 0 1 3 
 Mental component summary 1 0 0 1 
 Physical 
symptoms/problems 
0 0 1 1 
 Role physical 1 0 2 3 
 Physical functioning 3 0 0 3 
 Physical component 
summary 
1 0 0 1 
 Social functioning 2 0 1 3 
 Overall quality of life score 
(SF-36) 
1 0 0 1 
 General/global quality of life 
(single item) 
0 0 3 3 
Other measures Spiritual wellbeing 0 0 1 1 
 Existential issues 0 0 1 1 
 Palliative care needs 0 1 2 2 







Figure 1. Flowchart showing the numbers of articles screened and included. 
 
  


































Records excluded based 
on title/abstract 
(n=518) 
Full-text articles assessed 
for eligibility 
(n=270) 
Full-text articles excluded, with 
reasons (n=257) 
 
 No COPD sample (n=155) 
 No Lung cancer sample 
(n=59) 
 No empirical data(n=15) 
 Qualitative only (n=10) 
 Not focused on burden 
(n=18) 






Figure 2: Meta-analysis of results from two studies comparing the Modified Borg 
Dyspnea Scale in people with lung cancer and people with chronic obstructive 
pulmonary disease (COPD).  
 
 
Figure 3: Meta-analysis of results from two studies comparing the Hospital Anxiety 
and Depression Scale (HADS) in people with lung cancer and people with chronic 
obstructive pulmonary disease (COPD) 
 
 
Figure 4: Meta-analysis of results from 5 studies comparing Karnofsky Performance 





Supplementary Table 2: Results from 11 studies comparing burden from lung cancer with chronic obstructive pulmonary disease (COPD) 
Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
Symptoms Anxiety/ depression HADS (33) Mean (SD) depression in lung 
cancer vs COPD: 7.22 (5.16) vs 
10.18 (3.95), p<0.01 
Mean (SD) anxiety in lung cancer vs 
COPD: 7.20 (5.25) vs 11.44 (4.76), 
p<0.0001 
Proportions with clinically relevant 
scores on either scale: 52% lung 
cancer vs 90% COPD 
    
     (34) Proportion of clinically significant 
depression: 32% vs 49%, (no p-
value reported) 
  Median (IQR) anxiety: 7(4-10) 
vs 6 (3-10), p=0.641 
Median (IQR) depression: 6 (4-
9) vs 7 (4-11), p=0.228 
Proportion of clinically 
significant anxiety: 42% vs 42 
%, (p-value not reported) 
     (29)     No statistically significant 
difference (p>0.01 ) 
     (30)     No p values reported. Graphs 
suggest 25% have 
suggestive/probable anxiety 
and almost 50% have 
suggestive/probable 
depression in both groups 
  Depression BDI (35) Mean (SD): 17.04 (10.07) vs 20.19 
(10.54), p=0.032  
    
  MSDS (36)     No statistically significant 
difference in proportions with 





Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
  Mood POMS (13)   Median (25th, 75th percentile), 
anxiety in people dying within 2 
months: 1.33 (0.67, 2.00) vs 
1.17 (0.67, 2.67), p-value not 
reported. 
Median (25th, 75th percentile) 
anxiety in all people: 0.83 
(0.17-1.50) vs 0.83 (0.33, 
1.67), p-value not reported 
Depressive affect in all people, 
median (25th, 75th percentile): 
0.38 (0.00, 1.13) vs 0.38 (0.00, 
1.00), p-value not reported. 
  Distress DT (31)     Mean (SD, range) of symptom 
distress: 4.5 (2.3, 0-10) vs 4.6 
(2.4 0-10), p=0.77 
   MSAS-
PSYC 
(30)     Average distress associated 
with six psychological 
symptoms in lung cancer vs 
COPD: 1.1 (range 0-3.4) vs 1.3 
(range 0.1-3.5), p=0.36 
  Suicide risk Suicide risk 
screening 
(38)     Proportion (%) of people with 
moderate to high levels of 
symptom (reported as not 
significant, no value given): 
Suicidal thoughts: 18 (14.0%) 
vs 18 (23.7%), Negative 
thoughts: 23 (17.8%) vs 20 
(26.3%), Behavioural 
symptoms: 18 (14.0%) vs 13 
(17.1%) 
   Suicide 
tendency 
scale 
(38) Mean (SD) of suicide tendency 
score: 2.5 (0.3) vs 2.6 (0.4), (p value 
not reported) 
    
 Feeling sad MSAS-SF (30)     28 (57%) vs 23 (38%), p=0.05 
 Nervousness MSAS-SF (30)     23 (48%) vs 35 (59%), p=0.24 
 Irritability MSAS-SF (30)     23 (47%) vs 23 (38%), p=0.82 
 Worrying MSAS-SF (30)     32 (65%) vs 39 (67%), p=0.83 
 Feeling anxious or 
worried 
POS (30)   Median 1 vs 0.5 (p=0.01) 
 




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 Life worthwhile POS (30)     Median 0 vs 1 (p=0.56) 
 Feeling good POS (30) Median 1 vs 0 (p=0.05)     
  Pain  Ad hoc 
measure - 
interview 
(13)   Proportions with severe pain*: 
27% lung cancer vs 17% 
COPD (p=.002) 
Proportions of people dying 
within 2 months with severe 
pain**: 35% lung cancer vs 
28% COPD (p=>0.05) 
 MSDS (36)     Moderate to severe pain: 51% 
vs 38%, p=0.08 
Number of people reporting 
pain as a symptom, p>0.05 
 MSAS-SF (30)   Pain 34 (69%) vs 26 (43%), 
p=0.01 
  
 MSDS (38)   Pain mean 3.96 vs 2.43 
(textual description that 
difference was significant) 
  
 MQOL (37)   Pain 20.6% vs 6.0% (no p 
value given but significance 
assumed) 
  
 SF-36 (34)     Bodily pain: 74 (41-80) vs 62 
(41-100), p=0.559 
 SF-36 (33) p≤0.05     
 SF-36 (35)   Bodily pain: 54.72 (34.57%) vs 
67.90 (33.15%), p=0.006 
  
   POS (30)   Median 1 vs 3 (p=0.00)   
 Breathlessness Ad hoc 
measure - 
interview 
(13) Proportions with severe 
breathlessness*: 26% lung cancer 
vs 48% COPD (p=.001) 
  Proportions of people dying 
within 2 months with severe 
breathlessness: 46% lung 




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 MBS (31) Number (%) with breathlessness: 24 
(75%) vs 48 (96%), p=0.005 
Number (%) with continuous 
breathlessness: 7 (22%) vs 26 
(52%), p=0.007 
Number (%)with severe 
breathlessness: 3 (9%) vs 16 (32%) 
    
 MBS (32) Total number (%) of episodes of 
breathlessness: 189 (100%) vs 403 
(100%), p<0.001 
Mean (SD) Borg score: 4.2 vs 6.2, 
p<0.001 
Number (%) severe Borg scores, 
(≥5): 4.2 (1.9%) vs 6.2 (2.1), 
p<0.001 
Median (range) of breathlessness 
episodes (min): 5.0 (0.3-120 
minutes) vs 7.0 (0.02-600 minutes), 
p=0.002 
Percentage of breathlessness 
episodes: 
≤5 min: 62.5% vs 50.0%, p=0.001  
≤10 min (cumulative): 79.9% vs 
69.1%, p=0.003 
≤20 min (cumulative): 95.7% vs 
86.5%, p=0.001 
Timing of breathlessness episodes: 
Only during the day: 96.7% vs 
74.0%, p<0.001 
  Frequency of breathlessness 
episodes: 
>3 per day: 19.1% vs 24% 
1-3 per day: 55.5% vs 47.7% 
Weekly: 24.3% vs 27.3%. No 
p-value  
 MBS (29)       No statistically significant 
difference (p value not 
reported)  




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 MSAS-SF (30) Number and proportion with each 
symptom with lung cancer vs COPD:  
Shortness of breath: 42 (86%) vs 58 
(97%), p=0.04 
Severity of breathlessness in lung 
cancer vs COPD: median 3 (range 
0-7) vs median 3 (range 0-10) 
Score (range) of distress due to 
breathlessness with lung cancer vs 
COPD: 3.2 (range 0-4) vs 4 (range 
0-4), p=0.01 






(34) Median (IQR) for lung cancer 2.0 
(1.0-3.0) vs for COPD 4.0 (4.0-5.0) 
(p<0.05)  
    
 (37)     Proportion scoring 0 or 1: 
58.7% vs 45.4%, p=0.21 
Proportion scoring ≥2: 41.2% 
vs 54.5%, p=0.21 
  SAS (39) Mean (SD) breathlessness severity 
for lung cancer vs COPD at 3 time 
points (days before death):  
T1 (60-53): 3.1 (2.6) vs 5.0 (3.0) 
T2 (30-23): 3.6 (2.7) vs 5.2 (2.8) 
T3 (7-0): 4.4 (2.5) vs 5.8 (2.8) 
  
 Shortness of breath MSDS (38) Mean severity of symptoms (0-10): 
shortness of breath: 3.59 vs 4.56 
    
 MQOL (37) Proportions with lung cancer vs 
COPD who have symptoms: 
shortness of breath 11.1% vs 57.5% 
(p=.000001)  





Median 2 vs 2 (p=0.18)   
 Chest tightness MSDS (38) Mean severity of symptoms (0-10): 
Chest tightness: 2.82 vs 3.32 
    
 Cough MSAS-SF (30)     Cough: 38 (78%) vs 37 (62%), 
p=0.07 
 MSDS (38)   Mean severity of symptoms (0-
10) 





Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 MQOL (37)     Cough 1.5% vs 6.0%;  
 Dysphagia MSDS (36)     No statistically significant 
difference in proportions with 
lung cancer vs COPD reporting 
 Dry mouth MSAS-SF (30) 32 (65%) vs 51 (85%), p=0.02     
 Fatigue MSDS (36)     No statistically significant 
difference in proportions with 
lung cancer vs COPD reporting 
 MSDS (38)   Mean severity of symptoms (0-
10): 3.36 vs 2.97 
  
 MQOL (37)   Tiredness 8 (12.6%) vs 4 
(12.1%) 
(Trouble sleeping) 11 (17.4%) 
vs 1 (3.0%), p>0.05 
 MSAS-SF (30)     (Trouble sleeping ) 25% vs 
33%, p=0.68 
 Lack of energy MSAS-SF (30)     Lack of energy: 41 (84%) vs 58 
(97%), p=0.14 
 Vitality SF-36 (34)     Median (IQR): 40 (20-65) vs 40 
(29-60), p=0.927 
   SF-36 (33) p≤0.05     
 Lack of 
strength/weakness 
MSDS (38)     Lack of strength, weakness: 




(37)      4.7% vs 15.1%, p>0.05 
 Feeling drowsy/ 
difficulty sleeping 
MSAS-SF (30)   Feeling drowsy 43 (87%) vs 41 
(68%), p=0.02 
Difficulty in sleeping 25 (51%) 
vs 33 (55%), p=0.68 
  Insomnia  MSDS (38)   Mean severity of smptoms (0-
10): 4.11 vs 3.59 
  
 MSDS (36) People with lung cancer were more 
likely to experience insomnia 
(p<0.005) 




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 Poor 
appetite/anorexia 
MSDS (38)   Mean severity of symptoms (0-





(37)      17.4% vs 3%, p>0.05 
 MSAS-SF (30)     Lack of appetite: 36 (74%) vs 
24 (40%), p=0.00 
 MSDS (36)     No statistically significant 
difference. 
 Weight loss MSAS-SF (30)     27 (56%) vs 23 (38%), p=0.62 
 Nausea MSDS (36) 
 
People with lung cancer were 






(37)     6.3% vs 0%, p>0.05 
 Abdominal 
distention 
MSDS (38)   3.39 vs 3.11   
 Feeling bloated MSAS-SF (30) 15 (31%) vs 31 (52%), p=0.03     




(37)   Proportions with lung cancer vs 
COPD who have symptoms: 
constipation 22.2% vs 0.0% 
  
 Diarrhoea MQOL 
symptom 
scales$ 
(37)     6.3% vs 0%, p>0.05 
 Urine retention Ad hoc five 
point scale, 
nurse rated 
(14) 68.2% vs 36.7%, p=0.048.     
 Sweats MSAS-SF (30)     19 (39%) vs 30 (51%), p=0.21 
 Changes in skin MSAS-SF (30) Changes in skin: 17 (35%) vs 35 
(60%), p=0.01 
    











Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 Oedema Ad hoc five 
point scale, 
nurse rated 
(14) 95.5% vs 46.7%, p<0.001     
 Delirium Ad hoc five 
point scale, 
nurse rated 
(14)   46.7% vs 13.6%, p=0.017   






et al., 2010) 
Numbness in hands/feet MSAS-SF (Bausewein, Booth, Gysels, 
Kühnbach, et al., 2010) 
 Thirst MSDS (38) (Score out of 10) 3.13 vs 3.48     
 "I don't look like 
myself" 
MSAS-SF (30)     26 (53%) vs 29 (48%), p=0.62 
 Problems with sex       28 (58%) vs 19 (32%), p=0.01   
 Symptoms other 




Median 1 vs 0 (p=0.01)   
 Total number of 
symptoms 
Ad hoc five 
point scale, 
nurse rated 
(14)     Median (25th, 75th percentile) 
number of symptoms in lung 
cancer vs COPD: 10.0 (8.0, 
12.0) vs 10.0 (8.0-13.0), 
p=0.666 
 Mean severity of all 
symptoms 
MSDS (38) Mean (median, range) severity of all 
symptoms: 24.31 (25, 1-92) vs 26.17 
(21.5, 2-73) 
    
 Average frequency 
and distress caused 
by all MSAS 
symptoms 
TMSAS (30)     Average frequency and 
distress caused by all 32 
MSAS symptoms in lung 
cancer vs COPD: 1.1 (range 0-
2.7) vs 1.2 (0.3-2.5), p=0.73 
 Average frequency 
of four psychological 
symptoms and 
distress associated 
from six physical 
symptoms 
MSAS-GDI (30)     Average frequency of four 
psychological symptoms and 
distress associated from six 
physical symptoms in lung 
cancer vs COPD: 1.6 (range 0-




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 Average of distress 




(30)     Average of distress associated 
with 12 physical symptoms in 
lung cancer vs COPD: 1.5 




KPS (33) Mean (SD) of KPS: 66.9 (9.2) vs 
62.5 (10.4), p=<0.05 
    
 (34) Mean (SD) for lung cancer 74.2 
(14.3) vs for COPD 62.0 (13.0) 
(p<0.05) 
    
 (29)     Mean (SD) for lung cancer 66 
(11.7) vs for COPD 62 (10.9), 
p=0.11 (Sig Lev 5%) 
 (31) Mean (SD, range): 80.0 (13.7, 40-
90) vs 69.4 (14.3, 30-90), p=0.001  
    
 (35) 73.5 ±19.0 vs 61.0 ± 11.2, p=0.001      
 EADL 
Scale 
(33) Mean (SD) of EADL limitation: 9.4 
(4.1) vs 11.3 (4.2), p<0.05  
    
 Proportion who are house-bound: 
36% vs 82% (no p-value reported) 
    
 Proportion who are chair-bound: 
10% vs 36%, (no p-value reported)  
    
 KADL (13) Mean ADL dependencies:1.46 vs 
1.63, p=0.004  
    
 GARS (34) Median (IQR) of ADL: 12 (11-17) vs 
18 (15-22), p<0.001 
    
 Median (IQR) of IADL: 12 (9-17) vs 
16 (13-19), p=0.006 
    
 PPS (36) Low score (%): 14.1% vs 21.6%, 
p=0.026 
Medium  score (%): 56.3% vs 
64.9%, p=0.026 
High scores (%): 29.7% vs 13.5%, 
p=0.009 





SF-36 (34) Median (IQR): 30 (20-42) vs 21 (14-
35), p=0.03 




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 (33) p≤0.05     
 (35)  Mean (SD): 42.29 (19.96) vs 25.44 
(15.23) 0.001 
    
QOL Social support MQOL (37) Median (IQR) 7.5 (6.5-9.0) vs 5.5 
(3.5-8.0), p=0.002 
    
 Psychological 
support 
MQOL (37)   Median (IQR) 6.0 (5.0-8.6) vs 
8.0 (6.0-9.5), p=0.01 
  
 Role emotional SF-36 (34)     Median (IQR): 33 (0-100) vs 50 
(0-100), p=0.309 
   (33)     p>0.05 
   (35) Mean (SD): 41.33 (46.21) vs 27.67  
(41.86), p=0.03 
    
 Mental Health SF-36 (34)     Median (IQR): 72 (40-80) vs 68 
(48-80), p=0.651 
   (33) p≤0.05     
 SF-36 (35) Mean (SD): 57.68 (23.21) vs 47.84 
(22.08) p=0.002 
    
 Mental Component SF-36 (35) Mean (SD): 47.93 (26.10) vs 36.07 
(20.79), p=0.001 
    
 Physical symptoms 
and problems 
MQOL (37)     Median (IQR) 5.3 (4.0-7.1) vs 
5.0 (3.8-5.8), p=0.34  
 Role physical SF-36 (34)     Median (IQR): 0 (0-25), vs 0 
(0-0), p=0.452 
 (33)     p>0.05 
 (35) 12.25 (25.99) vs 3.00 (10.22), 
p=0.001 
    
 Physical functioning SF-36 (35) Median (IQR): 42.90 (29.60) vs 
22.40 (22.55), p=0.001 
    
 (33) p≤0.05     
 (34) Median (IQR): 50 (25-75) vs 10 (0-
25), p<0.001 




Level Construct Measure Article Worse in COPD Worse in lung cancer No significant difference   
 Physical component 
summary 
SF-36 (35) Median (IQR): 38.04 (21.60) vs 
29.69 (14.35), p=0.001 
    
 Social functioning SF-36 (34)     Median (IQR): 63 (25-75) vs 38 
(25-75), p=0.374 
 (33) p≤0.05     
 (35) Mean (SD): 51.12 (35.31) vs 39.37 
(30.27), p=0.012 
    
 Overall quality of life 
score 




 General/global QOL Ad hoc 
measure 
(36)     General QOL item p=0.37 
Poor QOL (%): 25.0% vs 
15.5% 
Fair QOL (%): 51.9% vs 58.6% 
Good QOL (%): 23.1% vs 
25.0% 
   MQOL (37)     Median (IQR): 5.0 (4.0-6.7) vs 
5.0 (5.0-8.0), p=0.13 
 
 
Ad hoc five 
point scale, 
nurse rated 
(13)     Median: 4 vs 4, p=0.058 
Other Spiritual wellbeing FACIT-SP-
12 
(37)     Median (IQR) of total FACIT-
SP-12: 26 (21-36.2) vs 27 
(16.0-38.0), p=0.81 
Meaning and Peace domain: 
18 (15.0-24.0) vs 18 (10.2-
25.5), p=0.56 
Faith domain: 8 (6.0-11.0) vs 8 
(4.0-14.0), p=0.66 
 Existential issues MQOL       Median (IQR): 6.5 (5.0-7.8), 
p=0.07 




Overall scores were similar 
between disease groups (p 









Median total POS 11 vs 8 
(p=0.02); total POS plus 12 vs 
10 (p=0.03); wasted time 0 vs 0 
(p=0.00)  
Median information score 0 vs 
0 (p=0.05); sharing feelings 0 
vs 0 (p=0.93); practical matters 
(0 vs 0 (p=0.49) 
 
* results for patient report; ** results for surrogate report; $=chi-square calculated from data reported in article; ADL – Activities of Daily Living; BDI - Beck Depression 
inventory; COPD – Chronic Obstructive Pulmonary Disease; DT – Distress Thermometer; EADL – Extended Activities of Daily Living; EORTC QLQ-LC13 – European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (Lung Cancer); FACIT-SP-12 – Functional Assessment of Chronic Illness Therapy – 
Spiritual Wellbeing, 12 item scale; GARS - Groningen Activities of Daily Living Restriction Scale; HADS - Hospital anxiety and depression scale; IQR – Interquartile range; 
KADL – Katz Activities of Daily Living; KPS – Karnofsky Performance Scale; MBS - Modified Borg Dyspnea Scale; MQOL – McGill Quality of Life; MRC – Medical Research 
Council; MSAS-GDI - Memorial Symptom Assessment Scale, Global Distress Index; MSAS-Psyc – Memorial Symptom Assessment Scale, Psychological symptoms; MSAS-
SF – Memorial Symptom Assessment Scale, Short form; MSDS – McGill Symptom Distress Scale (?); POMS – Profile of mood states; PPS Palliative Performance Scale; 
QOL – Quality of life; SAS – Symptom Assessment Scale; SD – Standard deviation; SF-36 – Medical Outcomes Scale Short Form 36; SGRQ – St George’s Respiratory 
Questionnaire (COPD specific); TMSAS – Total Memorial Symptom Assessment Scale; vs - versus. 
 
